Consensus BioCryst Pharmaceuticals, Inc.

Stocks

BCRX

US09058V1035

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 01/08/2026 am IST			5-day change	1st Jan Change
8.980 ^USD	-2.81%		-3.85%	+15.13%

15/07	BioCryst Pharmaceuticals, Inc. Announces Appointment of David W. Jenkins as Chief Scientific Officer, Effective July 15, 2026	CI
07/07	RBC Capital Adjusts BioCryst Pharmaceuticals Price Target to $14 From $13, Maintains Outperform Rating	MT

Evolution of the Average Target: BioCryst Pharmaceuticals, Inc.

Evolution of the Target Price: BioCryst Pharmaceuticals, Inc.

Changes in Analyst Recommendations: BioCryst Pharmaceuticals, Inc.

fa6a77.5VV2i9LUDxWz1Yw0P9zbuG3p6I4m7EBX5z5Y-pMnMG0.3T0s7LyCXyXliuZjaa2c9yyMpMd-pHhhr3c0z6dfagCNI0-ynbFiZMKFxQ~6bfa17cf50eb64a553379c2d6eeff50d

Analysts' recommendations: BioCryst Pharmaceuticals, Inc.

07/07	RBC Capital Adjusts BioCryst Pharmaceuticals Price Target to $14 From $13, Maintains Outperform Rating	MT
07/04	RBC Capital Adjusts BioCryst Pharmaceuticals PT to $14 From $13, Maintains Outperform Rating	MT
25/03	BioCryst Shares Remain Undervalued, RBC Says	MT
27/02	Wedbush Adjusts Price Target on BioCryst Pharmaceuticals to $22 From $21, Maintains Outperform Rating	MT
30/01	RBC Cuts Price Target on BioCryst Pharmaceuticals to $13 From $14, Keeps Outperform Rating	MT
08/01	RBC Cuts Price Target on BioCryst Pharmaceuticals to $14 From $15, Keeps Outperform Rating	MT
30/12	BioCryst Pharmaceuticals Face Numerous Important Catalysts in 2026, Wedbush Says	MT
15/25/15	RBC Raises Price Target on BioCryst Pharmaceuticals to $15 From $14, Keeps Outperform Rating	MT
08/25/08	RBC Lifts Price Target on BioCryst Pharmaceuticals to $14 From $13, Keeps Outperform Rating	MT
01/25/01	Evercore ISI Downgrades BioCryst Pharmaceuticals to In Line From Outperform, Lifts Price Target to $8 From $12	MT
30/25/30	Wedbush Raises Price Target on BioCryst Pharmaceuticals to $18 From $16, Maintains Outperform Rating	MT
06/25/06	RBC Raises Price Target on BioCryst Pharmaceuticals to $13 From $11, Keeps Outperform Rating	MT
25/25/25	RBC Capital Adjusts Price Target on BioCryst Pharmaceuticals to $11 From $10, Keeps Outperform Rating	MT
07/24/07	JMP Securities Adjusts Price Target on BioCryst Pharmaceuticals to $15 From $14, Maintains Market Outperform Rating	MT
18/23/18	BioCryst Pharmaceuticals Receives Upgrade From RBC to Outperform From Sector Perform, Price Target Raised to $10 From $9	MT
04/23/04	Jefferies Upgrades BioCryst Pharmaceuticals to Buy From Hold, Price Target is $11	MT
04/23/04	RBC Raises Price Target on BioCryst Pharmaceuticals to $9 From $8, Keeps Sector Perform, Speculative Risk	MT
13/23/13	BofA Securities Upgrades BioCryst Pharmaceuticals to Buy From Neutral, Price Target is $10	MT
07/23/07	RBC Trims BioCryst Pharmaceuticals' Price Target to $8 From $9, Keeps Sector Perform Speculative Risk Rating	MT
20/23/20	Evercore ISI Lowers Price Target on BioCryst Pharmaceuticals to $10 From $13, Maintains Outperform Rating	MT
06/23/06	RBC Capital Adjusts BioCryst Pharmaceuticals Price Target to $9 From $10, Maintains Sector Perform - Speculative Risk Rating	MT
22/23/22	Needham Upgrades BioCryst Pharmaceuticals to Buy From Hold With $14 Price Target	MT
22/23/22	RBC Adjusts Price Target on BioCryst Pharmaceuticals to $10 From $12, Maintains Sector Perform Rating	MT
02/22/02	Evercore ISI Upgrades BioCryst Pharmaceuticals to Outperform From In Line With $16 Price Target	MT
02/22/02	RBC Trims BioCryst Pharmaceuticals' Price Target to $13 From $14 on Revised Estimates, Keeps Sector Perform Rating, Speculative Risk Qualifier	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	BIOCRYST PHARMACEUTICALS, INC.					+133.85%
	WUXI APPTEC CO., LTD.					+17.16%
	ARGENX SE					+20.44%
	BIONTECH SE					+34.66%
	INSMED INCORPORATED					+98.97%
	WUXI BIOLOGICS (CAYMAN) INC.					+21.54%
	GENMAB A/S					+28.71%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+17.22%
	EXELIXIS, INC.					-1.82%
	PHARMAESSENTIA CORPORATION					+1.26%
	Average					+37.20%
	Weighted average by Cap.					+27.39%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.980USD

Average target price

21.00USD

Spread / Average Target

+133.85%

High Price Target

32.00USD

Spread / Highest target

+256.35%

Low Price Target

12.00USD

Spread / Lowest Target

+33.63%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

RBC Capital Markets
Wedbush
Evercore ISI
JMP Securities
Jefferies & Co.
BofA Securities
Needham & Co.
Barclays
Oppenheimer
Piper Sandler
JPMorgan Chase
Cantor Fitzgerald
HC Wainwright
Cowen